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ABSTRACT
Inhibition of PIM and AXL Kinases as Potential Treatments for a Variety of Hematological
Malignancies and Solid Tumors
Kent J. Carpenter
Department of Physiology and Developmental Biology, BYU
Master of Science
This thesis is divided into three chapters. In each case, the goal is to achieve inhibition of
a growth kinase (PIM or AXL) and subsequent arrest of cell growth and induction of apoptosis
(in vitro cell culture models) or decrease in tumor volume (in vivo xenograft studies).
Chapter one and chapter two discuss inhibition of proviral integration site for Moloney
murine leukemia virus (PIM) kinases. The three PIM kinases, PIM-1, PIM-2, and PIM-3, are a
subfamily of serine/threonine kinases that are known to be involved in signaling pathways as
downstream effectors of signal transducer and activator of transcription-5 (STAT5) signaling and
inhibitors of apoptosis. PIM kinases are implicated in a large percentage of hematological
malignancies and solid tumors. Because they have been shown to correlate with disease
progression and poor prognosis in many of these conditions, PIM kinase inhibitors are being
developed and investigated for therapeutic use.
The aim of this study in chapter one was to evaluate the role of PIM 1, 2 and 3 in
urothelial carcinomas, using second generation Pan-PIM kinase inhibitor TP-3654. Retrospective
immunohistochemical analysis of bladder cancer specimens found that PIM 1, 2, and 3 was
expressed in a significant number of cases. PIM-1 was expressed in 4 bladder cancer cell lines
and TP-3654 treatment was able to inhibit BAD phosphorylation to induce apoptosis.
The second aim of this study was to investigate the effects of TP-3654 on the interaction
of c-MYC with PIM kinase family members. The data indicate that PIM-1 only interacts with cMYC in the acute myeloid leukemia (AML) and multiple myeloma (MM) cell lines studied, and
that PIM-1 siRNA knockdown or treatment with TP-3654 is able to decrease this interaction.
The third chapter discusses inhibition of the receptor tyrosine kinase Axl. Pancreatic
cancer is a highly lethal disease characterized by malignant cells that rapidly disseminate from
the primary tumor to form local and distant metastases. Axl is overexpressed in over 50% of
pancreatic cancers and expression of Axl in these cancers is highly associated with a poor
prognostic outcome for patients. Small molecule inhibitors of AXL are currently under
investigation, as AXL is associated with cell migration mediated by epithelial-mesenchymal
transition (EMT). The aim of this study was to investigate the effects of a small molecule
inhibitor of AXL, TP-0903, on pancreatic cancer cell lines. Consistent with the known function
of Axl, TP-0903 inhibited Gas6-induced migration and invasion of pancreatic cancer cells in
vitro and potently induced apoptosis. Additionally, we found that inhibition of AXL decreased
expression of EMT marker genes and induced mesenchymal pancreatic cancer cell lines to take
on an epithelial phenotype. TP-0903 also significantly inhibited the growth of pancreatic cancer
cell lines grown in xenograft tumor mouse model and taken together, the results suggest Axl is a
potential therapeutic target in pancreatic cancer and TP-0903 as a potential therapeutic agent.
Keywords: STAT5 signaling, Bcl-2, BAD, apoptosis, carcinoma, oncogene, migration,
metastasis, EMT, xenograft
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CHAPTER 1: A Small Molecule Inhibitor of PIM Kinases As a Potential Treatment for
Urothelial Carcinomas
Kent J. Carpenter1, Jason M. Foulks2, Bai Luo3, Yong Xu3, Anna Senina3, Rebecca Nix3, Ashley
Chan3, Adrianne Clifford3, Marcus Wilkes3, David Vollmer3, Benjamin Brenning3, Shannon
Merx3, Shuping Lai3, Michael V. McCullar3, Koc-Kan Ho3, Daniel J. Albertson4, Lee T. Call5,
Jared J. Bearss6, Sheryl Tripp7, Ting Liu4, Bret J. Stephens5, Alexis Mollard5, Steven L. Warner5,
Steven B. Kanner3, and David J. Bearss5
Authors Affiliation: 1. Department of Physiology and Developmental Biology, BYU, Provo, UT.
2. AlloCure Inc., Salt Lake City, UT. 3. Astex Pharmaceuticals Inc., Salt Lake City, UT. 4.
Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT. 5. Tolero
Pharmaceuticals, Inc., Lehi, UT. 6. Huntsman Cancer Institute, University of Utah, Salt Lake
City, UT. 7. R&D, ARUP Laboratories, Salt Lake City, UT.
Abstract
The proto-oncogene PIM kinases (PIM-1, PIM-2, PIM-3) are serine/threonine kinases that are
involved in a number of signaling pathways important to cancer cells. PIM kinases act in
downstream effector functions as inhibitors of apoptosis and as positive regulators of G1-S phase
progression through the cell cycle. PIM kinases are upregulated in multiple cancer indications,
including lymphoma, leukemia, multiple myeloma, prostate, gastric, and head & neck cancers.
Overexpression of one or more PIM family members in patient tumors frequently correlates with
poor prognosis. The aim of this investigation was to evaluate PIM expression in low- and highgrade urothelial carcinoma, and to assess for expression that may contribute to disease
progression and serve as a potential site for targeted therapy. One hundred and thirty seven cases
of urothelial carcinoma were included in this retrospective study of surgical biopsy and resection
specimens from the University of Utah Department of Pathology (retrieved from 2008-2011).
Our second generation PIM inhibitor, TP-3654, displays sub-µM activity in pharmacodynamic
marker modulation, proliferation and 2D colony formation assays using the UM-UC-3 bladder
cancer cell line. TP-3654 was also found to induce apoptosis in the T24, RT4, and UM-UC-3
bladder cancer cell lines. TP-3654 displays favorable hERG and CYP inhibition profiles
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compared with the first generation PIM inhibitor, SGI-1776, and has demonstrated excellent oral
bioavailability. In vivo xenograft studies using a bladder cancer cell line model show that PIM
kinase inhibition can reduce the growth of this tumor model suggesting that PIM kinase
inhibitors may be active in human urothelial carcinomas.
Introduction
The serine/threonine family of PIM kinases were first identified as proto-oncogenes
activated in T-cell lymphomas induced by murine leukemia viruses. The PIM kinase family
comprises three members (PIM-1, PIM-2, and PIM-3) with six different isoforms from alternate
translation initiating sites (1-5). Although the PIM kinase family is transcriptionally and
translationally regulated in cells, these kinases lack a regulatory domain and are constitutively
activated when expressed (6-10).
Expression of PIM-1 is induced by several cytokines, which often activate STAT5 in
conjunction with PIM-1. In fact, the Pim kinases are target genes of STAT3 and STAT5
signaling and are correlated with levels of STAT signaling (11-15). They often form complexes
with Hsp70 and Hsp90 for stabilization, but are eventually polyubiquitinated for proteasomal
degradation (11-15).
Although they were first implicated in human acute myeloid leukemia (AML) cases, PIM
kinases are over-expressed in many different types of malignancies including hematologic and
solid tumors. Specifically, over-expression has been identified in bladder, prostate, head & neck,
and several hematologic cancers. Over-expression of PIM kinases is often associated with poor
prognosis in each of these cancers. The PIM kinases have a variety of downstream targets that
are thought to contribute to tumor growth. In particular, PIM kinases target the pro-apoptotic
Bcl2-associated death promoter (BAD) family members and inhibit apoptosis (6-10).
2

In addition, it has been shown in prostate tumors that PIM-1 and c-MYC associate
together, resulting in transcriptional upregulation and stabilization of c-MYC. Such prostate
tumors exhibited higher Gleason scores and differentiation (16-20). Functionally, expression of
PIM kinases in tumors correlates with increased cell survival and reduced apoptosis, implicating
the family members as attractive targets for disruptive therapy.
Crystal structures for both PIM-1 and PIM-2 have been used to understand their unique
ATP binding pocket and for computational and medicinal chemistry efforts to develop inhibitors.
The hinge region of PIM kinases is unusual in that it contains a proline not generally present in
serine/threonine kinase hinges, as well as other unique residues in the ATP binding cleft (21-26).
Astex Pharmaceuticals, Inc. (formerly SuperGen, Inc.) developed an imidazopyridazine based
inhibitor, SGI-1776, that exhibited potent anti-PIM activity both in vitro and in vivo in a variety
of preclinical models (27-30). Studies have demonstrated that SGI-1776 exhibited potent antitumor activity in preclinical models of FLT3-ITD mutant AML (30-32). Investigators have
demonstrated that the observed activity in this model system may be due to the predominant antiFLT3 activity (33). In contrast, models without the FLT3-ITD mutation were sensitive to SGI1776, suggesting PIM-specific activity may be responsible for the observed anti-proliferative
effects (34-39). Ultimately, SGI-1776 was evaluated in a phase I clinical trial recruiting patients
with either prostate cancer or non-Hodgkin’s lymphoma. However, the trial was terminated
early due to a narrow therapeutic window, likely attributed to inhibition of the cardiac potassium
channel hERG (human Ether-à-go-go-Related Gene) also observed with SGI-1776 in functional
assays.
Our recent efforts focused on identifying a novel PIM kinase inhibitor with a unique antikinase profile and attractive pharmaceutical properties. In this report, we describe the discovery
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and characterization of a second-generation small-molecule PIM kinase inhibitor, TP-3654 (SGI
9481), which exhibits potent activity against all three PIM kinases, but with reduced activity
against FLT3. Further, oral administration of TP-3654 led to reduced tumor growth of
established human bladder carcinoma xenografts at safe and tolerated doses.
PIM-1, 2, and 3 expression has been well characterized in several leukemic and prostate
cancers. In addition, it has been shown that PIM-1 was observed in invasive and non-invasive
urothelial carcinoma specimens, with a higher incidence in invasive cancer (40). Because PIM
kinases’ role in bladder cancer is less well characterized, we sought to further evaluate PIM
expression in low- and high-grade urothelial carcinoma. Seventy-two cases of urothelial
carcinoma were included in this retrospective study of surgical biopsy and resection specimens
from the University of Utah Department of Pathology. We further sought to evaluate the activity
of TP-3654 in bladder cancer cell lines and xenograft models. Overall, the data presented here
provide preclinical activity to support the potential application of this inhibitor in urothelial
carcinomas.
Materials and Methods
Synthesis of TP-3654
TP-3654 (4-((3-(3-(Trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino) -transcyclohexyl)propan-2-ol) was prepared according to United States Patent Application Publication
US2012/0058997 (Imidazo[1,2-B]pyridazine and pyrazolo[1,5-A]pyrimidine derivatives and
their use as protein kinase inhibitors).
PIM Kinase IC50 and Ki Determinations
PIM kinase Ki determinations, TP-3654 selectivity screens and IC50 determinations were
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performed by Reaction Biology (Malvern, PA). For Ki determination, PIM-1, PIM-2 or PIM-3
were incubated with 10-dose, 3-fold serial dilutions of TP-3654 starting with 10 µM using five
different concentrations of ATP (25, 50, 100, 250 and 500 µM ATP for PIM-1; 5, 10, 20, 50 and
100 µM ATP for PIM-2 and PIM-3), and the activity was measured at 0, 5, 10, 15, 20, 30, 45,
60, 75, 90, 105 and 120 minutes. The data was analyzed in a Michaelis–Menten plot to
determine apparent Km and Ki values using GraFit software using a mixed inhibition equation for
global fit. For selectivity, 1 µM TP-3654 was tested against 336 kinases at a concentration of
10µM ATP. IC50 determinations of PI3K (α, β, δ, and γ) and all kinases inhibited >50% from the
initial screen were performed using 10-dose, 3-fold serial dilutions of TP-3654 starting with
10µM at Km ATP concentrations for each kinase.
Cell Lines
The T24, RT4, J82, and UM-UC3 bladder cancer cell lines were obtained directly from the
American Type Culture Collection (ATCC) in Manassas, VA, USA. These cell lines were
passaged for less than 6 months before use in the described assays and were authenticated by
ATCC. The MV4-11 and other cell lines used were not authenticated by the authors.
hERG Assay
TP-3654 was tested for effect on hERG potassium channels by automated patch clamp method
(QPatchHTX) at WuXi AppTec (Shanghai, China). Chinese hamster ovary cells stably expressing
hERG potassium channels from Aviva Biosciences were tested with TP-3654 at six
concentrations, 3-fold dilution starting at 30 µM with a final DMSO concentration of 0.15%, and
compared to vehicle (negative) control and Amitriptyline (positive) controls. Percent of control
(vehicle) values were calculated in duplicate for each concentration of drug, and curve-fitting
and IC50 calculations were performed by QPatch Assay Software.
5

Statistical Analysis and IC50/EC50 Determination
Statistical analyses were performed by parametric ANOVA test. IC50 and EC50 values were
determined using GraphPad Prism software (La Jolla, CA).
shRNA Transduction
UM-UC-3 cells (2.5x105) were seeded in a 6-well plate in complete RPMI 1640 media, and
allowed to adhere overnight at 37°C in 5% CO2. Cells were transduced with 8 µg/mL polybrene
(Sigma-Aldrich) and Lentiviral particles at an MOI of 50 based on titer values pre-determined by
Sigma-Aldrich using a p24 ELISA for each batch of shRNA. Following overnight transduction,
viral particle containing media was removed and replaced with fresh complete media, and cells
were cultured for an additional 48h at 37°C in 5% CO2. Cells were trypsinized and fractions of
the transduced cells were collected for colony formation growth assays, while the remaining cells
were collected for RNA and protein isolation.
RT-PCR
RNA from 0.5x106 cells was isolated on a QIAcube (Qiagen, Santa Clarita, CA) using the
protocol for purification of total RNA from animal cells (QIAshredder homogenization and oncolumn DNase digest), and quantified using a Nanodrop 8000 spectrophotometer (Thermo
Electron, West Palm Beach, FL). Total RNA (1 µg) was converted to cDNA in a 20 µl reaction
using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) by incubating the reaction
components for 5min at 25°C, 30min at 42°C, followed by 5min at 85°C. The cDNA reaction (2
µl) was used in a 20 µl PCR multiplex reaction using 1X FAM-labeled PIM-1, VIC-labeled actin
Taqman primer sets and the Taqman gene expression master mix from Life Technologies on an
iQ5 Real-Time PCR machine (Bio-Rad). An 8-point, half-log standard curve was generated for
PIM-1 and actin messages using RNA from untreated cells. A linear trendline (with an R
6

squared value >0.99) was generated by plotting log concentrations of standard vs. Ct values
generated from the real-time PCR reactions. Relative message levels from shRNA treated
samples were calculated based on the standard curve, normalized to actin and compared to the
non-target shRNA control.
Colony Formation Assay
For shRNA growth experiments, 500 UM-UC-3 cells were seeded in a 12-well plate 48 hours
post-transduction and cultured for 8-10 days at 37°C in 5% CO2. Cells were fixed with 4%
paraformaldehyde in PBS, washed twice with PBS, and stained with a crystal violet solution (1%
crystal violet, 10% ethanol in water). Stained cells were washed thrice with water, and imaged
after drying on a GelCount colony counter (Oxford Optronix Ltd., Oxford, UK). Total staining
intensity per well was determined by lysis of cells with 200 µl of Triton X-100 lysis buffer (1%
Triton X-100, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA). Lysates (100 µl) from
each well were transferred to a clear 96-well plate and absorbance at 560 nm was determined on
an Envision microplate reader. IC50 values were determined using GraphPad Prism software.
For compound treated PC-3 and UM-UC-3, cells were seeded and stained as above, but were
incubated with various concentrations of TP-3654 or DMSO one day after seeding.
Cell Lysis and Western Blots
In all applications, cells were washed with cold PBS and then treated with cell lysis solution
(Cell Signaling). Lysates were centrifuged at 14,000g at 4oC according to the protocol. Protein
levels were then measured and normalized using the BCA Protein Assay (Pierce). Normalized
amounts of lysate were then run on pre-cast gels according to the manufacturer protocol, using
MOPS running solution (Invitrogen). Gels were transferred using the iBlot system (Invitrogen)
and then blocked for one hour in a 5% non-fat dry milk TBS-tween (TBST) solution. Blots were
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treated with specified antibodies (all provided by Cell Signaling) diluted 1:1000 in 5% bovine
serum albumin-TBST solution separately on a blot shaker overnight at 4oC. Blots were rinsed 3
times for 5 minutes each after antibody treatments, according to the protocol. The blots were
treated with rabbit secondary antibody solutions (Cell Signaling) for 1 hour at room temperature
diluted 1:1000 in a 5% non-fat dry milk TBST solution. As with the primary antibodies, the blots
were rinsed 3 times for 5 minutes each before imaging with an ECL kit. The blots were stripped
and then re-treated overnight with actin when used as a loading control. As explained
previously, the blots were treated in antibody solution diluted 1:1000 in 5% BSA TBST solution
overnight. Blots were treated with mouse secondary antibody (Pierce) and imaged as described
previously.
Apoptosis Assays
Percentages of apoptotic bladder cancer (T24, RT4, UM-UC3) cells were measured using the
violet radiometric membrane asymmetry probe/dead cell apoptosis kit for flow cytometry kit
(Life Technologies). Cells were seeded in 6-well plates at a concentration of 2.5x105 cells per
well, allowed to grow for 12 hours, and then drug treated with the specified concentrations of
TP-3654 for 24 hours. Dyes were added and measured on the flow cytometer and gates were set
according to the protocol from Invitrogen. Two independent experiments were carried out under
identical conditions and then averaged to yield the given data. Treatment of UM-UC3 cells with
cisplatin for 24 hours was used as a positive control.
PIM-1 siRNA
UM-UC3 bladder cancer cells were seeded in 6-well plates at a concentration 2.5x105 cells per
well, allowed to grow for 12 hours, and then transfected with 75pmol of PIM-1 siRNA
(QIAGEN), 75 pmol of prepared control siRNA (QIAGEN), or left untreated. Cells were
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transfected using 6µL of Lipofectamine 2000 reagent (Invitrogen) diluted in Opti-MEM
according to the protocol. Cells were treated with siRNA and transfection reagent for 24 hours
before cell lysis, as described above. Levels of PIM-1 were analyzed by Western blot to confirm
knockdown.
TP-3654 Treatment
UM-UC3 bladder cancer cells were seeded in 6-well plates at a concentration 2.5x105 cells per
well, allowed to grow for 12 hours, and then treated with 3, 1, and 0.3 and 0.03 µM of TP-3654
with 0.1% DMSO (vehicle) treated cells as a negative control. Cells were incubated with the
drug for 12 hours and then lysed as described previously.
Urothelial Carcinoma Pathology Cases
One hundred and thirty seven cases of urothelial carcinoma were included in this retrospective
study of surgical biopsy and resection specimens from the University of Utah Department of
Pathology (retrieved from 2008-2011). Tissue was stained with commercially available
antibodies against PIM-1, PIM-2, and PIM-3. Cases were classified into three groups according
to WHO criteria (invasive high grade urothelial carcinoma (n=84), non-invasive high grade
urothelial carcinoma/carcinoma in situ (n=32), and non-invasive low grade urothelial carcinoma
(n=21)). Individual cases were reviewed by two of the authors (DA/TL) and given a score (0-4)
based upon a percentage of cells demonstrating positive cytoplasmic and/or nuclear staining for
each antibody (<5%=0; 5-25%=1; 26-50%=2; 51-75%=3; >75%=4). A score of 2 or greater
was considered positive staining.
Tumor Xenograft Studies
Male and female Nu/Nu mice were purchased from Harlan Sprague Dawley (Indianapolis, IN).
Female Nu/Nu mice were used for all xenograft evaluations with the exception of the PC-3
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xenografts where male Nu/Nu mice were used. Cell lines were expanded in vitro in complete
media, and if adherent were harvested by trypsin-EDTA, centrifuged and resuspended in PBS
1:1 with Matrigel (BD Bioscienes). Cells were inoculated subcutaneously in the right hind flank
of mice. When tumors reached 100-200 mm3 by caliper measurement, mice were randomized
and dosing of TP-3654 or vehicle control began and continued every day for 5 days (QDx5) with
2 days off for 18-21 days. Tumor volumes and body weights were determined twice a week, and
tumor weights were measured at the completion of the translational xenograft studies.
Pharmacokinetic Study
Female SD rats with jugular vein catheters were acquired from Charles River Laboratories
(Wilmington, MA) and allowed to acclimate at Tolero’s laboratory facility for 3 days. Rats were
fasted (no food, but with water) for 12 hours prior to the dosing. Animals (3 per group) were
dosed with TP-3654 by oral gavage at a dose of 40 mg/kg in a volume of 400μL per 10g of body
weight. TP-3654 was formulated in a solution of 20% polysorbate 20. Animals dosed
intravenously were heated under a heat lamp prior to dosing to allow vasodilatation and
visualization of the tail vein. These animals were dosed with 2mg/kg of TP-3654 in a volume of
200μL per 10g of body weight. After injection, pressure was applied to the site for a few seconds
to stop bleeding from the injection. Immediately after each animal received the full dose, time
zero began and blood was collected at the following time points 1, 5, 25, and 30 minutes, and 1,
2, 4, 8, 24, and 48 hours post dose. At the designated time points, an empty 1 ml syringe was
used to clear the contents of the jugular vein catheter that had been pre-loaded with heparin and
discarded. A new empty syringe was used to draw 200μL of whole blood and the blood was
immediately added to EDTA-coated tubes with the appropriate labels. The tubes were gently
shaken to ensure the entire volume of blood interacted with the EDTA to avoid clotting. The
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collected blood was stored on ice until centrifugation and cryo-storage of plasma. A third syringe
containing heparin was used to reload the catheter to prevent clotting. After the blood was
collected it was centrifuged at 5000 rpm for 5 minutes at 4°C. The plasma layer was removed
and stored at -80°C until extraction and analysis. These steps were repeated until all time points
in the study were collected and properly stored. Plasma samples were extracted using standard
techniques and analyzed by LC-MS to quantify TP-3654 concentrations. Pharmacokinetic
parameters were determined using the PKSolver add-in program for Excel.
Results
A second generation PIM kinase inhibitor, TP-3654 (Fig. 1.1A), was discovered as a lead
candidate based on improved potency against PIM-1 and PIM-2 and decreased hERG activity in
vitro as compared to SGI-1776. TP-3654 was tested against a panel of 340 kinases at 1 µM, and
inhibited 38 kinases by >50%. IC50 determinations of 38 protein kinases and 4 additional lipid
kinases (PI3K family) revealed 22 kinases with IC50 values below 300 nM (Fig. 1.1B). TP-3654
displays at least 10-fold or greater selectivity for PIM-1 compared to any other kinase tested.
One notable kinase family inhibited by TP-3654 was PI3K (γ, δ, and α), while selectivity against
FLT3 was reduced by nearly 100-fold relative to SGI-1776 (Table 1.1).
The cellular potency of TP-3654 was determined by measuring its effect on baseline
phosphorylation of BAD, a known substrate of PIM, on serine 112 by over-expression of PIM-1
and BAD in HEK-293 cells. Over-expression of the catalytically inactive mutant PIM-1 (K67M)
did not increase phosphorylation of BAD compared to BAD transfection alone and was used as a
negative control to subtract BAD phosphorylation by cellular kinases other than PIM-1. TP3654 demonstrated potent PIM-1 specific cellular activity in the PIM-1/BAD over-expression
system with an average EC50 = 67 nM (Fig. 1.1C).

11

The over-expression models were helpful in establishing the anti-PIM activity of TP3654. Translational models with more clinical relevance were explored for PIM dependency
using shRNA knockdown. The UM-UC-3 urinary epithelial bladder carcinoma cell line was
used to verify and validate dependency on PIM-1 for growth. PIM-1 mRNA was significantly
reduced using two independent shRNAs targeting PIM-1 compared to the non-target shRNA
control (Fig. 1.2A). Further, PIM-1 protein was reduced using PIM-1 shRNA compared to nontarget shRNA, and 2D-colony growth was markedly reduced with PIM-1 knockdown (Fig.
1.2A), comparable to a previous report in the literature (40). Additionally, TP-3654 reduced
colony growth of UM-UC-3 and PC-3 cells (Fig. 1.2B and 1.2C), confirming the PIM-1
dependent growth for both cell lines.
Additional bladder cancer cell lines were tested for levels of PIM-1, 2, and 3 (Fig 1.3b).
Consistent with previous results, all 4 bladder cancer cell lines expressed high levels of PIM-1.
The UM-UC3 cell line expressed the highest levels of PIM-1 and PIM-2 (Fig 1.3b) and was the
most sensitive to TP-3654 in apoptosis assays (Fig 1.3a). For this reason, we continued our
studies in the UM-UC3 cell line, focusing on PIM-1. PIM-1 siRNA knockdown or treatment
with TP-3654 in UM-UC3 cells resulted in decreased levels of phosphorylated BAD (S112) (Fig
1.3c-d). To exclude the possibility that this pBAD decrease was due to off-target activity, we
measured levels of p4EBP1 (decreased p4EBP1 is also seen in apoptotic conditions) in parallel
with pBAD. We found no appreciable difference in levels of p4EBP1 in PIM-1 siRNA or TP3654 treated cells (Fig 1.3c-d), providing further evidence that PIM inhibition was the primary
reason for the pBAD decrease observed in TP-3654 treated cells and not activity of the
compound inhibiting AKT, another kinase that phosphorylates BAD in certain conditions.
Because PIM kinases have been implicated in number of cancers including hematological
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and prostate cancers (32, 33, 41-46), we sought to further evaluate PIM expression in low, high,
non-invasive, and invasive bladder cancer cases. Evaluation of PIM expression by
immunohistochemistry revealed a significant number of cases in which PIM was expressed in
greater than 25% of the neoplastic cell population (Fig 1.4, Table 1.2). Low grade non-invasive
tumors demonstrated the highest percentage of cases expressing PIM-1 (43%) and PIM-3 (52%)
while invasive high grade lesions demonstrated the lowest percentage of PIM-1 (12%) and PIM3 (13%) staining. PIM-2 was overexpressed in the majority of non-invasive high grade cases
(63%) and in a significant minority of invasive high grade cases (38%) and non-invasive low
grade cases (33%).
We next tested whether TP-3654 could inhibit the growth of established mouse xenograft
tumors using the UM-UC-3 and PC-3 solid tumor cell lines that were tested in vitro. Oral dosing
of 200 mg/kg of TP-3654 significantly reduced both UM-UC-3 and PC-3 tumor growth
measured by volume (caliper) and by final tumor weight, with no significant changes in body
weight or gross adverse toxicity (Fig. 1.5).
Previous studies showed that SGI-1776 exhibited favorable pharmacokinetic properties.
We therefore sought to determine if TP-3654 retained or possibly improved upon the
pharmacokinetic parameters of SGI-1776. A pharmacokinetic study in female rats was carried
out as described in the materials and methods section. Rats were orally dosed with TP-3654
formulated in 20% polysorbate 20 and compared to intravenous injected control (Fig 1.6). This
formulation showed favorable oral bioavailability at 39%. Using this formulation the Tmax for
TP-3654 was 1 hour with a half-life of 4.1 hours (Fig 1.6).
Discussion
PIM kinases play central roles in tumor cell survival and protection from apoptosis,
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implicating this family of kinases as valid therapeutic targets (16-19). To date, numerous
inhibitors of PIM kinases have been generated which exhibit growth suppressive activity in
tumor cell line models in vitro and in vivo (9, 11, 14, 17, 19, 25, 48, 49). Previous PIM kinase
inhibitors demonstrated antitumor activity in xenograft models of FLT3-ITD mutant AML and
renal cell carcinoma (32, 43-47). We have developed a novel small molecule PIM kinase
inhibitor that reduces the growth of solid tumor xenografts where the tumorigenicity is mediated
by over-expression of PIM-1 or PIM-2, as well as human bladder carcinoma tumors. The
combination of inhibiting all three PIM family members together in one compound may promote
the observed antitumor activity.
Although the expression and activity of PIM kinases are well characterized in AML and
prostate cancers, we sought to further evaluate the role of PIM kinases in bladder carcinomas.
Previous work evaluating bladder carcinoma indicated that PIM-1 was expressed in over 80% of
malignant tissues compared with normal epithelia, and expression was enhanced when
comparing specimens derived from bladder cancer patients with invasive versus non-invasive
tumors (40). Further, it was shown that shRNA knockdown of PIM-1 in bladder carcinoma cell
lines reduced the growth of the cells in vitro, indicating a prominent role for PIM-1 in bladder
carcinoma (40). We evaluated TP-3654 in the bladder cancer model UM-UC-3 in vitro and
showed that the compound was able to induce similar effects as PIM-1 shRNA/siRNA mediated
knockdown (Fig 1.2a-c, Fig 1.3c-d).
In addition to the in vitro data, examination of surgical resection cases of urothelial
carcinoma revealed PIM kinase expressed in a significant number of cases when evaluated by
immunohistochemistry. There was significant variation across the different groups.
Interestingly, PIM-1 and PIM-3 showed a much higher percentage of cases staining in low grade
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non-invasive carcinoma as compared to invasive high grade urothelial carcinoma where only a
small minority retained positive staining. PIM-2 in comparison was expressed highest in a
majority of non-invasive high grade lesions and in more than one-third of invasive lesions
suggesting PIM-2 expression remains important in more aggressive clinical disease. These
findings suggest that expression of PIM kinases contributes to uncontrolled growth in low and
high grade non-invasive carcinoma and a smaller number of high grade invasive tumors.
TP-3654 reduced the growth of established UM-UC-3 xenografts (Fig 1.5), further
suggesting that PIM-1 over-expression in patient bladder tumors may be sensitive to
perturbation. As our pharmacokinetic study was performed in rats, it is important to note that offtarget activity may have played a role in the therapeutic effect seen in the mouse xenografts.
Additional pharmacokinetic, xenograft, and ex vivo studies are needed to fully understand the
potential benefits of PIM kinase inhibition in urothelial carcinomas.
The rationale for targeting PIM kinases for the development of cancer therapies includes
their over-expression in a variety of malignancies, correlation of high expression levels with poor
patient prognosis, their oncogenicity when over-expressed in cells, their role in tumor cell
survival as demonstrated by expression knockdown in multiple cancer types, and the
development of inhibitors with preclinical activity which are emerging as clinical agents (29,
37). Together, these data support the long-standing effort to generate a therapeutic platform
from which to target this family of cell survival kinases. Although the initial clinical evaluation
of SGI-1776 was halted due to a narrow therapeutic window, the significant potential for
therapeutic application of improved drug candidates remains. Given the rapid pace of discovery,
optimization and development of new PIM kinase inhibitors, one or more will likely gain
momentum as a key part of the armamentarium of treatments for both solid and hematologic
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malignancies, including urothelial carcinomas.
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CHAPTER 2: Inhibition of PIM Kinases Results in Downregulation of Oncogenic CMYC
Signaling and Induction of Apoptosis in Hematological Malignancies, Including Acute Myeloid
Leukemia and Multiple Myeloma
Kent J. Carpenter
Department of Physiology and Developmental Biology, Brigham Young University, Provo, Utah
84602, USA
Abstract
The three PIM kinases, PIM-1, PIM-2, and PIM-3, are a subfamily of serine/threonine
kinases that are known to be involved in signaling pathways as downstream effectors of signal
transducer and activator of transcription-5 (STAT5) signaling and inhibitors of apoptosis. PIM
kinases lack a regulatory domain and are largely controlled at the transcriptional level. PIM
kinases are implicated in a large percentage of hematological malignancies and solid tumors.
Because they have been shown to correlate with disease progression and poor prognosis in many
of these conditions, PIM kinase inhibitors are being developed and investigated for therapeutic
use. More recent studies have indicated that PIM-1 plays a role in the upregulation of oncogenic
c-MYC signaling, a hallmark of many cancers.
The aim of this study was to investigate the effects of TP-3654 on the interaction of cMYC with PIM kinase family members. The data indicate that PIM-1 only interacts with c-MYC
in the AML and multiple myeloma (MM) cell lines studied, and that PIM-1 siRNA knockdown
or treatment with TP-3654 is able to decrease this interaction. In addition, TP-3654 potently
induced apoptosis in the AML and MM cell lines studied.
These results suggest that second-generation PIM kinase inhibitor TP-3654 is effective at
inhibiting PIM kinases and their downstream target c-MYC. These results contribute to the
growing body of evidence that PIM kinase inhibitors have therapeutic potential in AML and
introduce them as a potential target in MM.
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Introduction
Cancer continues to be a worldwide epidemic. Cancers have accounted for more than
10% of recorded deaths each year in the world every year since 2007. Global cancer rates are
expected to rise due to an aging population and lifestyle changes in the developing world 1.
Hematological malignancies account for approximately 9.5% of newly diagnosed cancers in the
United States each year, and new treatments are needed to battle the problem of malignant cell
resistance to common chemotherapeutics1, 2.
The serine/threonine family of PIM kinases were first identified as proto-oncogenes
activated in T-cell lymphomas induced by murine leukemia viruses3. The PIM kinase family is
comprised of 3 family members (PIM-1, PIM-2, and PIM-3) with six different isoforms from
alternate translation initiating sites3-5. Although the PIM kinase family is transcriptionally and
translationally regulated in cells, these kinases lack a regulatory domain and are constitutively
activated when expressed3-5.
Expression of PIM-1 is induced by several cytokines, which often activate STAT5 in
conjunction with PIM-1. In fact, the PIM kinases are target genes of STAT3 and STAT5 and are
correlated with high levels of STAT signaling6. They often form complexes with Hsp70 and
Hsp90 for stabilization, but are eventually polyubiquitinated for proteasomal degradation3-5.
Although they were first implicated in human AML cases, PIM kinases are overexpressed in many different types of malignancies including hematologic and solid tumors.
Specifically, over-expression has been identified in bladder, prostate, head & neck, and other
hematologic malignancies. Over-expression of PIM kinases is often associated with poor
prognosis in each of these cancers7-9. Additional research suggests that targeting PIM kinases
may be beneficial to halt disease progression in hematological malignancies where PIM kinases
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are expressed, including AML, MM, and certain types of lymphomas2, 3, 10-14.
The PIM kinases have a variety of downstream targets that are thought to contribute to
tumor growth. In particular, PIM kinases target the pro-apoptotic Bcl2-associated death promoter
(BAD) family members and inhibit apoptosis4-6, 13-15. Inhibitors of PIM kinases have been
developed and effectively induce apoptosis in AML, MM, prostate, bladder, and other cancer
cell lines9, 16, 17. These inhibitors are also able to restore sensitivity of resistant cell lines to some
chemotherapeutics, such as cisplatin, because PIM kinases actively upregulate expression of the
efflux transporters MDR-1 and BCRP9, 16, 17.
In addition, it has been shown in prostate tumors that PIM-1 and c-MYC associate
together, resulting in transcriptional up-regulation and stabilization of c-MYC. Such prostate
tumors exhibited higher Gleason scores, indicating greater disease progression and poorer
prognosis8. c-MYC is an important oncogenic transcription factor that is able to regulate gene
expression through binding of enhancer box sequences and recruitment of histone acetyl
transferases (HATs)3, 16. The MYC gene was first discovered in Burkitt’s lymphoma patients and
is located on chromosome 810, 11. Like PIM kinases, c-MYC is highly expressed in many cancers,
most notably hematological malignancies, where preliminary data has shown that PIM kinases
are able to directly and indirectly activate c-MYC10, 11.
PIM kinase inhibitors are currently in development with some in clinical trials because of
their potential to inhibit disease progression and induce apoptosis in AML cells. Crystal
structures for both PIM-1 and PIM-2 have been used to understand their unique ATP binding
pocket and for computational and medicinal chemistry efforts to develop inhibitors. First
generation PIM kinase inhibitor SGI-1776, developed by Astex Pharmaceuticals (formerly
SuperGen Inc.), was evaluated in a phase I clinical trial recruiting patients with either prostate
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cancer or non-Hodgkin’s lymphoma16. Eventually, the trial was terminated due to a narrow
therapeutic window due to inhibition of the cardiac potassium channel hERG (human Ether-àgo-go-Related Gene)9, 16.
A second-generation PIM kinase inhibitor TP-3654, owned by Tolero Pharmaceuticals in
Lehi, Utah, is under evaluation because it has less off target inhibition (FLT3 kinase activity)
than SGI-1776 and no appreciable hERG inhibition. TP-3654 was the primary PIM kinase
inhibitor used in these studies.
The aim of this study was to further evaluate the association of PIM kinases with c-MYC
in acute myeloid leukemia (AML) and multiple myeloma (MM) cell lines, where higher
expression of PIM kinases has been associated with disease progression and poor prognosis.
Materials and Methods
Synthesis of TP-3654
TP-3654 was obtained from Tolero Pharmaceuticals Inc., currently located in Lehi, UT. TP-3654
(4-((3-(3-(Trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino) -transcyclohexyl)propan-2-ol) was prepared according to United States Patent Application Publication
US2012/0058997 (Imidazo[1,2-B]pyridazine and pyrazolo[1,5-A]pyrimidine derivatives and
their use as protein kinase inhibitors).
Cell Lines
Cell lines were obtained from the American Type Culture Collection (ATCC) agency located in
Manassas, Virginia. Cells were cultured in 75mL flasks in 10% fetal bovine serum (FBS)
supplemented media. Each cell line was grown in the media recommended on the website of
ATCC.
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Cell Lysis and Western Blots
In all applications, cells were washed with cold PBS, treated with cell lysis solution (Cell
Signaling), and then scraped when applicable. Lysates were centrifuged at 14,000g at 4oC and
the supernatant used for protein quantification, according to the protocol. Protein levels were
measured and normalized using the BCA Protein Assay (Pierce). Normalized amounts of lysate
in electrophoresis buffer were then boiled and run on pre-cast gels according to the manufacturer
protocol, using MOPS running solution (Invitrogen). Gels were transferred using the iBlot
system (Invitrogen) and then blocked for one hour in 5% non-fat dry milk TBS-tween (TBST)
solution. Blots were treated with specified antibodies (all provided by Cell Signaling) diluted
1:1000 in 5% bovine serum albumin (BSA)-TBST solution separately on a blot shaker overnight
at 4oC. Blots were rinsed 3 times for 5 minutes each after antibody treatments, according to the
protocol. The blots were treated with rabbit secondary antibody solutions (Cell Signaling) for 1
hour at room temperature diluted 1:1000 in a 5% non-fat dry milk (NFDM) TBST solution. As
with the primary antibodies, the blots were rinsed 3 times for 5 minutes each before imaging
with an ECL kit.
Apoptosis Assays
For the AML and MM cell lines, drug treated cells were analyzed for apoptosis by measuring the
expression of cleaved caspase-3, rather than flow cytometry. In this case, cells were lysed and
analyzed for caspase-3 expression by Western blot, as described previously. Cells were seeded at
1x106 million cells per well in 6-well plates and drug treated immediately. Cells were incubated
in the presence or absence of TP-3654 for 24 hours prior to lysis and analysis of caspase-3
expression.
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PIM-1 siRNA
MV4-11 cells were transfected with 75pmol of PIM-1 or control siRNA using 6 or 9µL of
Lipofectamine 2000 reagent (Invitrogen) diluted in Opti-MEM according to the protocol. Cells
were treated with siRNA and transfection reagent for 24 hours before cell lysis, as described
above. Levels of PIM-1 were analyzed by Western blot (Fig 2.2a) to confirm knockdown.
TP-3654 Immunoprecipitation Treatment
For the MV4-11 (AML) and ARP-1 (MM) cell line drug treatments, 2x106 cells were placed in
suspension culture in 6 well plates and drug treated at the specified concentrations at the same
time. Cells were incubated with the drug for 12 hours before lysis. The lysates were then
analyzed for immunoprecipitation as described below.
Immunoprecipitation
The interaction of PIM kinases and c-MYC in AML and MM cell lines was evaluated by
immunoprecipitation (IP). Cell lysates were prepared and protein levels quantified as described
previously. For each sample, enough lysate was added to obtain 200µg of total protein in 1mL of
cell lysis solution, according to the protocol from Santa Cruz Biotechnology. 10µL of primary
antibodies optimized for IP (Santa Cruz Biotechnology) were added and the lysates incubated for
1hr at 4oC. After the hour incubation, 20µL of G-protein agarose beads (Santa Cruz
Biotechnology) were added to each sample followed by overnight incubation at 4oC. The
following day, samples were spun at 5000rpm at 4oC to pellet the beads, according to the
protocol. Beads were then washed with 1mL of cold phosphate buffered saline (PBS) solution.
The wash was repeated 4 times before the beads were resuspended in electrophoresis buffer
(Invitrogen). The resuspended beads were then boiled and run on SDS-PAGE gels as described
for Western blots previously. Blots were incubated with cMYC primary antibody optimized for
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Western blotting (Santa Cruz Biotechnology) at 1:200 in 5% BSA, TBST as described
previously for Western blots. Mouse secondary antibody (Pierce) was used after overnight
incubation at 1:5000 in 5% NFDM TBST solution for an hour at room temperature. Blots were
washed after each antibody incubation step as described previously. For the MV4-11, KASUMI1, and ARP-1 cell lines, lysates treated with beads alone and lysates treated with AXL+beads
(the AXL protein does not interact with cMYC) were used as negative controls (Fig 2.1a-c lanes
1-2). Lysates were treated with cMYC antibody for both the IP and blotting steps as a positive
control (Fig 2.1a-c lanes 3).
Results
In the MV4-11 and KASUMI-1 AML cell lines and the ARP-1 MM cell line, expression
of PIM-1, 2, and 3 was evaluated. Consistent with previous results, PIM-1 was expressed in all
the cell lines studied and PIM 1, 2, and 3 was expressed in the MV4-11 cell line (Fig 2.1a). This
is likely the reason that the MV4-11 cell line was more sensitive to TP-3654 (Fig 2.3). In all 3
cell lines studied, PIM-1 alone interacted with cMYC (Fig 2.1b-d). This finding is most
significant in the MV4-11 cell line, where PIM-1, 2 and 3 are highly expressed (Fig 2.1b). As
TP-3654 is a potent PIM-1 inhibitor (Table 1.1), we expected that TP-3654 treatment would
decrease the PIM-1-cMYC interaction observed in these cell lines. These results provide
evidence that TP-3654 does decrease this interaction (Fig 2.2b,c). Additionally, when MV4-11
cells were treated with PIM-1 siRNA, the PIM-1-cMYC interaction was eliminated almost
entirely (Fig 2.2a).
Discussion
In addition to our previous work in urothelial carcinomas, we sought to evaluate the role
of PIM-1’s interaction with cMYC in AML and MM cell lines. Even though PIM 1, 2 and 3 was
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expressed in the MV4-11 cell line (Fig 2.1a), PIM-1 alone interacted with cMYC in the same cell
line (Fig 2.1b). This PIM-1-cMYC interaction was observed in the other cell lines studied (Fig
2.1c-d), and this interaction was decreased within 12 hours of TP-3654 treatment (Fig 2.2b-c).
As a transcription factor, cMYC is a very difficult drug target in spite of the fact that it is
upregulated in many different types of cancers. These findings suggest that inhibition of PIM
kinases may present a way to indirectly decrease cMYC signaling. Further studies, including
chromatin immunoprecipitation (ChIP) analysis of downstream targets of cMYC are currently
underway to further analyze the effects of PIM kinase inhibition in AML and MM cells.
The rationale for targeting PIM kinases includes their over-expression in solid tumors and
hematological malignancies, their frequent correlation with poor prognosis, their role in
inhibition of apoptosis, and their oncogenicity when over-expressed in cells. In fact, PIM kinase
inhibitors are already in clinical trials and additional drug candidates are being explored. It is
clear that TP-3654 or other PIM kinase inhibitors will likely become a key part of the
armamentarium of treatments for both solid and hematological malignancies.
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CHAPTER 3: Inhibition of The Tyrosine Kinase Receptor AXL Blocks Cell Invasion and
Promotes Apoptosis in Pancreatic Cancer Cells
Kent Carpenter1, Alexis Mollard2, Lee Call3, Jared Bearss2, Hariprasad Vankayalapati2, Sunil
Sharma2, Mark Wade2, Marc D Hansen1, Steven L Warner3, and David J Bearss1,3
Authors Affiliation: 1. Department of Physiology and Developmental Biology, BYU, Provo, UT.
2. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. 3. Tolero
Pharmaceuticals, Inc., Salt Lake City, UT.
Abstract
Pancreatic cancer is virtually a uniformly lethal disease and a better understanding of the
molecular basis of this malignancy is needed to discover new ways to prevent or treat this deadly
disease. A central feature of malignant cells is their ability to disseminate from the primary
tumor and establish local and distant metastases. In most cases, cancer patients with localized
disease have significantly better prognosis than those with metastatic tumors and the majority of
cancer mortality is associated with metastatic disease rather than the primary tumor. The receptor
tyrosine kinase Axl is overexpressed in over 50% of pancreatic cancers and expression of Axl in
these cancers is highly associated with a poor prognostic outcome for patients. Axl is a TAM
family receptor tyrosine kinase involved in multiple aspects of tumorigenesis. Increased
expression of Axl is associated with increased oncogenic transformation, cell survival,
proliferation, migration, angiogenesis, and cellular adhesion. The known ligand for Axl is the
Growth Arrest Specific Gene-6 (Gas6) protein and it’s binding to Axl leads to Axl
autophosphorylation and activation of downstream signaling pathways including MAPK and
PI3K/Akt pathways. We discovered and developed a small molecule Axl kinase inhibitor, TP0903, and explored it for the effectiveness of targeting the Axl kinase in cell-based models of
pancreatic cancer. TP-0903 is a 2-((2,5-substitutedpyrimidin-4-yl)amino)-N,N-dimethyl benzene
sulfonamide that has low nanomolar (IC50 = 12 nM) activity against the Axl kinase in a
biochemical assays. In further biochemical evaluation, TP-0903 was shown to inhibit the entire
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TAM family of kinases (IC50 Axl = 12 nM; IC50 Mer = 60 nM; Tyro3 = 71% inhibition at 200
nM). TP-0903 inhibits a small number of additional kinases when screened in a kinase panel of
over 500 kinases and has demonstrated an ADMET profile suggesting it may be a potential
clinical candidate. In cell proliferation assays, TP-0903 significantly inhibited pancreatic cancer
cell growth at concentrations as low as 30 nM. In pharmacodynamic assays, TP-0903
dramatically inhibited Akt signaling (pAKT S473) downstream of GAS6 stimulation in
pancreatic cancer cell lines. Consistent with the known function of Axl, TP-0903 inhibited Gas6induced migration and invasion of pancreatic cancer cells in vitro and potently induces apoptosis.
Mechanistically, TP-0903 decreases the expression of genes involved in Epithelial-Mesenchymal
Transition (EMT) and induces cells to take on more epithelial phenotypes. TP-0903 also
significantly inhibited the growth of pancreatic cancer cell lines grown in xenograft tumor mouse
model and taken together, these results suggest Axl is a potential therapeutic target in pancreatic
cancer and TP-0903 as a potential therapeutic agent.
Introduction
Pancreatic cancer is a deadly disease characterized by high levels of malignant,
metastatic cells that have a high capacity to disseminate from the primary tumor and invade other
tissues (50-52). This metastatic progression is enhanced by tumor cell activation of epithelial-tomesenchymal transition (EMT), a developmental program in which epithelial cells assume a
mesenchymal phenotype during gastrulation and organogenesis, allowing single cell invasive
movement away from the ectodermal layer. EMT in cancer cells is associated with the
acquisition of many stem cell-like features and immunosuppression that cooperatively support
metastasis (53-56). The search for critical regulators of metastatic progression has focused on
proteins that promote EMT and provide signals that support cell migration and invasion. One
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such protein is the receptor tyrosine kinase Axl (57-59).
Axl belongs to the subfamily of RTKs called the TAM receptors. This subfamily includes
Axl, Tyro3 and Mer (59-64). The TAM receptors are defined by a combination of two
immunoglobin-like domains and dual fibronectin type III repeats in the extracellular region of
the protein. Two ligands, Gas6 (growth arrest-specific 6) and protein S have been identified for
the TAM receptors. These ligands are vitamin K-dependent proteins that exhibit 43% amino-acid
sequence identity and share similar domain structures (59-64). These proteins have a N-terminal
Gla domain containing 11 γ-carboxyglutamic acid residues followed by four epidermal growth
factor-like modules and a C-terminal sex hormone-binding globulin (SHBG)-like structure
consisting of two tandem laminin G domains. The SHBG domain is both necessary and
sufficient for TAM receptor binding and activation, whereas the Gla domain binds the negatively
charged membrane phospholipids and plays an important role in TAM-mediated phagocytosis of
apoptotic cells (59, 60, 70-75).
Axl was originally cloned from patients with chronic myelogenous leukemia and, when
overexpressed, it exhibits transforming potential (70-73). Axl overexpression has been reported
in a variety of human cancers including metastatic pancreatic cancer, colon cancer, thyroid
carcinoma, breast cancer and pancreatic cancer. Axl is highly expressed in metastatic prostate
cancer cells compared with normal prostate cells and other prostatic carcinoma cell lines (75-77).
Inhibition of Axl signaling by a dominant-negative receptor mutant (AXL-DN) suppresses
experimental gliomagenesis, migration and invasion, and leads to long-term survival of mice
after intracerebral glioma cell implantation compared with Axl wild-type transfected tumor cells
(78, 79). Additionally, Axl is detected at higher levels in metastases or malignant tumors than in
normal tissues or primary tumors, and a higher level is associated with a poor clinical outcome
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(50, 55, 79-82).
Axl seems to plays two critical roles in cancer cells. First as a transforming gene that is
overexpressed in human tumors, and secondly as a key mediator of the Gas6/Axl signaling
system that is activated in the vasculature (80-85). Unlike many RTK oncoproteins, Axl can
transform fibroblasts even in the absence of ligand (85-88). Therefore, Axl activation may be
mediated through dual mechanisms that can involve interaction of Axl with its endogenous
ligand, Gas6 as well as GAS6 independent activation (88-92). The Gas6/Axl system has been
shown to play an important role in vascular biology. GAS6/Axl signaling promotes cell growth,
antiapoptosis and migration in vascular smooth muscle cells, endothelial cells and fibroblasts
(92-95). Recent studies also indicate that Gas6/Axl signaling affects multiple cellular behaviors
required for neovascularization and maintaining vascular integrity (92, 94). These findings
indicate that Axl regulates processes fundamental for both tumorigenesis and angiogenesis.
It was recently reported that Axl is aberrantly expressed in over 50% of pancreatic
cancers and expression of Axl in pancreatic cancers confers an adverse prognostic influence (50,
59, 99). We have developed small molecule inhibitors that target Axl kinase activity and block
downstream signaling from the activated receptor. These compounds display activity in the low
nanomolar range and have been optimized to exhibit properties consistent with drug-like clinical
candidates. One compound, TP-0903, exhibits potent AXL inhibition in the low nanomolar range
and is currently being investigated for its clinical potential in pancreatic cancer.
Using established pancreatic cancer cell lines, we sought to evaluate the effects of TP0903 treatment on these cells. Overall, the data presented here suggest that inhibition of AXL
with TP-0903 results in suppression of EMT marker genes, decreased cell migration, and
induction of apoptosis in the pancreatic cancer cell lines studied.
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Materials and Methods
Biochemical Assays
Biochemical kinase assays were utilized to determine IC50 values for TP-0903 against these four
kinases. Reactions were run using Invitrogen’s TR-FRET LanthaScreen assay and using ATP
concentrations at the apparent Km for each kinase.
pAKT ELISA
Pancreatic cancer cell lines (PSN-1 and PL45) were serum starved overnight, treated for 2 hours
with TP-0903, and stimulated with Gas6 for 5 minutes. Lysates from these cells were analyzed
for total-Akt and phospho-Akt (Ser473) using the Meso Scale Discovery platform.
Migration Assays
In order to test for a role of AXL in cell migration, TP-0903 was applied to a panel of cancer cell
lines and migration measured. The cell line panel included a series of 8 pancreatic cell lines and
a breast cancer cell line, MDA-MB-XXX, with high AXL expression. Cells were seeded onto
collagen-coated wells of the Platypus Oris system, where a barrier prevents cells from accessing
the center of the well. After overnight culture, the barrier is removed, drug (5uM) is applied from
DMSO stocks and the cells are cultured for 16 hours to allow migration into the open area of the
well plate. Importantly, cells are grown in 10% serum conditions, conditions that result in
saturated activation of AXL signaling.
Apoptosis Assays
We assessed TP-0903’s ability to induce apoptosis in the PANC-1 and PSN-1 cell lines using the
violet radiometric membrane asymmetry probe/dead cell apoptosis kit for flow cytometry kit
from Invitrogen. Cells were seeded in 6-well plates at a concentration of 250,000 cells per well,
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allowed to grow for 48 hours, and then drug treated with the specified concentrations of TP-0903
for 24 hours. Dyes were added and measured on the flow cytometer and gates were set according
to the protocol. Cells were treated with 10µM cisplatin for 24 hours in the same manner as above
for use as a positive control.
Real Time PCR
Quantitative PCR analysis was performed using the StepOne Plus Real-time PCR system from
Life Technologies Inc. Cells were first seeded at a concentration of 250,000 cells per well in 6
well plates, allowed to grow for 6 hours, and then treated with specified concentrations of TP0903 for 2 hours prior to RNA isolation. RNA isolation was carried out using the RNeasy kit
(QIAGEN) according to the protocol, including treatment with the RNase-free DNase set from
the manufacturer. RNA levels were normalized using a nanodrop spectrophotometer (Life
Technologies). RT and PCR reactions were carried out using the SYBR-Green One Step RNA to
Ct kit (Life Technologies) according to the protocol for 20µL reactions. Commercially available
primers (QIAGEN Quantitect Primer Assays) were used to target the EMT genes Snail, Twist, Ecadherin, and AXL. Reactions for each EMT gene target were carried out in triplicate while the
18S loading controls were carried out in quadruplicate. ΔCT values were determined by
subtracting each treatment group from its corresponding 18S CT average. Δ ΔCT reactions were
determined by subtracting each drug treated group from the vehicle treated control groups.
Relative quantification was then determined from the ΔCT values. The data shown are the
averages from two independent experiments, both carried out in the same manner as described
above, with error bars denoting the standard error of the mean in each case.
Western Blots
Western blots were carried out to confirm real-time PCR results. Both the PSN-1 and PANC-1
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cell lines were again seeded in 6 well plates at a concentration of 250,000 cells per well, allowed
to grow for 6 hours, and then treated with varying concentrations of TP-0903. Cell lysis was
carried out 24 hours later using a standard cell lysis kit (Cell Signaling Technologies). Protein
levels were measured using the BCA protein assay (Pierce) according to the protocol. Lysates
were then normalized and run on pre-cast gels (Invitrogen) according to the Invitrogen protocol.
Gels were transferred using the iBlot system also available from Invitrogen. Blots blocked for 1
hour at room temperature in a 5% non-fat dry milk (NFDM) solution before leaving overnight at
4OC in antibody solutions. Antibody solutions (Cell Signaling Technologies) were prepared in a
5% bovine serum albumin (BSA) solution and diluted 1:1000. The next day, blots were treated
with the corresponding secondary antibodies for 1 hour at room temperature in a 5% NFDM
solution before imaging using a Western ECL detection kit.
Soluble AXL Data
Serum samples from cancer patients were evaluated for sAxl levels. The results indicate a
statistically significant difference between the mean of the control (CTL) group and the PDA
(panc) group (p < 0.05). Furthermore, there appears to be a subgroup of colon, lung, and PDA
patients with particularly high sAxl levels.
Xenograft Study
PSN-1 cells were implanted subcutaneously in mice and allowed to establish tumors. TP-0903
was orally administered to the mice daily (M-F) for three weeks. Tumor and body weight
measurements were taken twice a week.
Pharmacokinetic Data
Mice were dosed orally with 50 mg/kg TP-0903 and blood was collected at the indicated time
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points. Plasma samples were analyzed by mass spectrometry and standard PK parameters were
calculated from these data.
Results
TP-0903 is a Multi-Targeted Kinase Inhibitor With Potent Activity Against AXL
Our second-generation AXL inhibitor, TP-0903, was developed as an analogue to first
generation AXL inhibitor SGI-7079. Compared with SGI-7079, TP-0903 displays significantly
greater AXL inhibition at lower nanomolar concentrations (Fig 3.1).
Migration Assays
In these experiments different cell lines exhibit different rates of migration, as determined
by the amount of space covered by cells at the end of the experiment. In almost all cell lines
tested, a reduction in the amount of migration is observed. The observation is born out by
statistical analysis of the data sets for drug-treated and control conditions for each cell line; 6 of
9 cell lines showing a statistically-significant reduction in cell migration by student t-test (Fig
3.3).
TP-0903 Potently Induces Apoptosis in Pancreatic Cancer Cell Lines
In addition to our migration assays, we sought to determine which concentrations TP0903 was able to induce apoptosis in the pancreatic cancer cell lines studied. We found TP-0903
to significantly induce apoptosis in both the PANC1 and PSN-1 cell lines within 24 hours.
TP-0903 induced apoptosis at significantly higher levels at lower concentrations than our
cisplatin-treated positive controls (Fig 3.4).
AXL Inhibition by TP-0903 Significantly Reduces Expression of EMT Marker Genes
To further confirm our migration assay results, we sought to determine the effects of
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AXL inhibition with TP-0903 on EMT marker gene expression using the same two pancreatic
cancer cell lines PANC1 and PSN-1. First, the pancreatic cancer cell lines were treated with TP0903 in 6-well plates and their expression of EMT genes slug, snail, twist, and E-cadherin by
real-time PCR and Western blot analysis. For real-time PCR analysis, cells were treated with
drug for only 2 hours to avoid any potential apoptotic or dead cell interference in measuring
RNA levels. In both pancreatic cancer cell lines studied, we found that TP-0903 treated cells
expressed significantly less snail and twist (Fig 3.5a-b). As expected, E-cadherin levels increased
in each case relative to the vehicle-treated cells in a concentration-dependent manner (Fig 3.5ab). It is not clear, however, why lower concentrations of TP-0903 induced higher E-cadherin
expression compared to higher concentrations of TP-0903.
Western blot analysis of the EMT marker genes snail, slug, and E-cadherin showed a
similar trend (Fig 3.5c-d) for both cell lines studied. In this case, cells were treated in 6-well
plates as with the qPCR, but were treated for 24 hours to allow for a change in protein levels.
sAXL in Pancreatic Cancer
In order to understand the role of sAxl in cancer we have used an Axl ELISA on
conditioned media to detect sAxl levels quantitatively. In parallel, we have also evaluated Axl
mRNA expression by RT-PCR and Axl RTK protein expression by western blot (Figure 3.6AB). Interestingly, levels of Axl mRNA and sAxl were fairly well correlated (r2 = 0.61). Similarly,
protein levels as determined by western blot also showed good correlation with sAxl levels. For
example, the cell lines PL45, BxPC3, and HPAC had high levels of Axl protein expression and
were also among the highest for sAxl. HPAFII and Hs700T had the lowest expression of both
Axl protein and sAxl. These data suggest that in at least PDA cell lines, sAxl may serve as a
surrogate marker for monitoring the level of total Axl in the cancer cells. This finding may
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translate to the pancreatic cancer patient allowing a simple blood test evaluating sAxl levels to
predict patients with high levels of Axl in their tumors.
To determine if we can detect differential expression of sAxl in the serum of cancer
patients, we evaluated serum from a panel of breast (10), colorectal (10), lung (10), and
pancreatic (16) cancers using the Axl ELISA (Figure 3.6C). We also included serum from 23
individuals without cancer. There was significant overlap between the cancer groups and the
normal serum group, but the normal group did not have a single individual over the 40 ng/ml
level; whereas, a significant portion of the serum from cancer patients had sAxl levels higher
than 40 ng/ml. Serum from PDA patients had sAxl levels as high as 66 and 78 ng/ml. These
preliminary data suggest a subset of cancer patients with high levels of sAxl. To see if high sAxl
correlated with favorable or poor prognosis, we compared these data to the overall survival of
these cancer patients (lung and pancreas only). Two groups were created from the sAxl data.
The first group consisted of the patients with high sAxl (n = 4) and the second group included
patients with lower sAxl levels (n = 22). Although this data set is small (particularly the high
sAxl group), we saw an interesting positive correlation between sAxl levels and overall survival.
In other words, the few patients with the highest sAxl levels had the greatest overall survival.
TP-0903 Reduces Tumor Volume in Pancreatic Cancer Xenografts
In vivo xenograft studies of PSN-1 pancreatic cancer cells showed a significant reduction in
tumor volume (p<0.001) but an insignificant decrease in overall body weight (p>0.1) by
Student’s t-test (Fig 3.7 A, B). Pharmacokinetic studies indicated favorable bioavailability (Fig
3.7 C).
Discussion
Progress has been made in the treatment of pancreatic cancer in the past decade, but it is
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still largely incurable and many patients respond poorly to treatment. There is a clear need to
develop targeted therapies aimed to reduce the mesenchymal character of cancer cells in solid
tumors that are prone to metastasis, including pancreatic cancer. The receptor tyrosine kinase
AXL has been previously implicated in pancreatic cancer and is correlated with poor prognosis
in these cases (52, 53, 100). Because of the clear role of AXL in EMT and metastatic pancreatic
cancer, we sought to evaluate the ability of our second-generation AXL inhibitor, TP-0903, to
block pancreatic cancer cell migration and invasiveness.
TP-0903 was generated as a second-generation AXL inhibitor following SGI-7079.
Compared with SGI-7079, TP-0903 is far more potent against AXL and shows nanomolar
inhibition and toxicity in a variety of cancer cell lines. In addition to its inhibition of cell growth,
TP-0903 significantly reduced migration in 6 out of the 9 mesenchymal pancreatic cancer cell
lines studied.
To clarify that these migration results were the result of a decreased EMT phenotype in
the cancer cells, we further studied the effect of TP-0903 on EMT gene expression in those cell
lines showing highest AXL expression from the cell-line array. Real-time PCR and Western
blot results of the EMT genes slug, snail, and twist show that TP-0903 treatment caused the
cells to become less mesenchymal. As expected, E-cadherin expression increased with higher
drug treatment, indicating the cells had become more epithelial.
The benefit of treatment with TP-0903 may extend beyond a mesenchymal to epithelial
transition in malignant cells. In vitro, TP-0903 potently induced apoptosis in those cell lines
expressing the highest levels of AXL. Our in vivo PSN-1 cell line xenograft studies similarly
showed a significant reduction in tumor volume. Taken together, these results suggest that highly
metastatic, Axl-expressing pancreatic carcinomas may become less invasive and sensitive to
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perturbation when treated with AXL inhibitors.
While the role of AXL in cancer cells is established, we sought to evaluate the role of
soluble AXL (sAXL) in tumor progression and prognostic outcome. The activated GAS-6-AXL
complex is frequently cleaved from the cell membrane and left in the serum of cancer patients.
We first used cell line models and found a positive correlation between Axl mRNA and protein
expression and media sAXL levels. This preliminary data suggested that sAXL levels could be
used as a marker for total AXL levels in cancer cells and, subsequently, as a prognostic marker
for cancer patients.
To evaluate this hypothesis, we next moved to an ex vivo model, evaluating the serum of
a panel of breast, colorectal, lung, and pancreatic cancer patients for sAXL by ELISA. Serum
from cancer-free individuals was included as a control. Many of these patients had high levels of
sAXL, but these high levels did not necessarily correlate with poor prognosis. In fact, those
patients with the highest sAXL had a slightly better prognosis than those with lower sAXL
levels. It is important to note that the data set used consisted of only ten individuals, and that
correlation may not hold true in a larger population size. However, it is clear that sAXL levels in
cancer patients may not necessarily correlate with cellular Axl levels. It has been reported that
Gas-6 induced activation of Axl often results in a cascade event in which the receptor becomes
constitutively active. In other words, Axl is often activated in the absence of ligand. Because
sAXL is only found in a complex with Gas-6, it may be that many cells in metastatic tumors
express Axl that has not been activated by Gas-6 and cleaved.
The rationale for targeting Axl is borne out of the observation that pancreatic cancer
patients with metastatic disease frequently have poorer prognosis than early-stage disease. This
is true for many other cancers. For example, Axl has been shown as correlated with a
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mesenchymal phenotype in breast cancer cells and poor prognosis in breast tumors expressing
high levels of Axl (52). Similar results were seen in esophageal and hepatocellular carcinomas
(32, 53). We report that TP-0903 is able to not only inhibit migration but also induce apoptosis at
low concentrations in both in vitro and in vivo models of pancreatic cancer. Additionally, TP0903 displays favorable oral pharmacokinetics in both rat and mouse models, further
demonstrating the therapeutic potential of TP-0903 in pancreatic and other cancers with
metastatic potential.
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FIGURE LEGENDS
Figure 1.1: Structure and analysis of TP-3654. A, TP-3654 compound structure. B, Selectivity
analysis of TP-3654. IC50 values are shown for the most potently inhibited kinases. PIM kinase
values are Ki values, which were comparable to the IC50 determinations.

C, The PIM-1-

specific cellular EC50 of TP-3654 was determined in a phospho-BAD (S112) Surefire assay
using HEK-293 cells transfected with BAD and PIM-1. The graph represents data from a single
experiment, where the EC50 values from four independent experiments (avg = 67 nM) were
determined using GraphPad Prism software.
Figure 1.2: Validation of PIM-1 in solid tumor models in vitro. A, PIM-1 shRNAs or control
shRNA (non-target) were transfected into the UM-UC-3 bladder carcinoma cell line, and PIM-1
mRNA, PIM-1 protein and cell proliferation in a 2D colony formation assay were evaluated.
Cells were infected with lentiviral particles overnight, the media was changed and the cells were
collected at 48 hrs post-transduction for RNA or protein. A portion of cells were seeded in a 6well plate at 500 cells/well. Cells were fixed and stained after 10 days of growth. Data for PIM1 mRNA levels is the average (± standard deviation) of 2 independent experiments, while
Western blot and colony formation assays are representative of three independent experiments.
*p = 0.0028; **p = 0.0002. B, UM-UC-3 (bladder) or C, PC-3 (prostate) cancer cell lines were
seeded at 300 or 500 cells/well in a 12-well plate and treated the next day with titrated
concentrations of TP-3654 as indicated. Cells were grown for 10 or 6 days respectively, stained
for imaging and lysed for quantitation by absorbance at 560 nm. Data are representative of
independent experiments evaluating TP-3654 using UM-UC-3 and PC-3 cell lines, with an
average EC50 = 1.1 µM ± 0.4 µM (n=4) and 2.2 µM ± 0.2 µM (n=2), respectively.
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Figure 1.3: TP-3654 induces apoptosis and inhibits BAD phosphorylation in bladder cancer cell
lines. A, The percentage of apoptotic cells was measured using the violet radiometric membrane
asymmetry probe/dead cell apoptosis kit for flow cytometry kit from Life Technologies. Cells
were seeded in 6-well plates at a concentration of 250,000 cells per well, allowed to grow for 24
hours, and then drug treated with the specified concentrations of TP-3654 or cisplatin (for use as
a positive control) for 48 hours. Dyes were added and measured on the flow cytometer and gates
were set according to the protocol. The data shown for the TP-0903 treated cells are averages
with SEMs compiled from two independent experiments. B, 4 bladder cancer cell lines were
tested for basal levels of PIM1, PIM2, and PIM3. Untreated MV4-11 cell lysate was run as a
positive control and actin as a loading control. C, UM-UC3 cells were treated with PIM-1 or
control siRNA as described in Materials and Methods. Separate, identical blots were treated with
antibodies to measure levels of S112 phosphorylated BAD, total BAD, Th37/46 phosphorylated
4EBP1 and total 4EBP1 were measured. D, UM-UC3 Cells were treated for 12 hours with 3, 1,
0.3 and 0.03 µM of TP-3654 and the same proteins analyzed as in C.
Figure 1.4: PIM2 Kinase Expression in Urothelial Carcinoma Cases. A. Immunohistochemcial
stained sections of Non-invasive low grade papillary urothelial carcioma (200x) B. Noninvasive high grade urothelial carcinoma (400x) C. Invasive high grade urothelial carcionoma
(400x) D. No expression in an invasive high grade urothelial carcinoma (400x)
Figure 1.5: TP-3654 inhibits the growth of established solid tumor xenografts. A, UM-UC-3
bladder carcinoma cells (5 x 106) were implanted per Nu/Nu mouse, with 12 mice/group. Mice
were dosed with TP-3654 orally at 200 mg/kg QD, 3 wks, 5 days on 2 days off (red) or with
vehicle (black). Caliper measurements (left panel) and tumor weights at the end of the study
(middle panel) are shown. No significant change in body weights were observed (right panel). *p
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= 0.0028; **p = 0.02. B, PC-3 cells (7.5 x 106) were implanted per male Nu/Nu mouse, with 12
mice/group. Mice were dosed with TP-3654 orally at 200 mg/kg QD, 3 wks, 5 days on 2 days
off (red) or with vehicle (black). Caliper measurements (left panel) and tumor weights at the end
of the study (middle panel) are shown. No significant change in body weights were observed
(right panel). *p = 0.007; **p = 0.0002.
Figure 1.6: Oral PK data for TP-3654. Plasma levels of TP-3654 (ng/mL) in female SD rats were
determined using LC/MS. Rats were dosed either by intravenous injection at 2 mg/kg, or orally
at 40 mg/kg animal body weight. A simple formulation consisting of 10% polysorbate 20
resulted in the highest exposure (or area under the curve), and showed the highest bioavailability
when compared to the IV injected animals.
Figure 2.1: PIM-1 alone interacts with cMYC in AML and MM Cell Lines. A, MV4-11,
KASUMI-1 AML cells and ARP-1 MM cells express high levels of PIM-1. MV4-11 cells
express PIM-1, 2 and 3. B, IP analysis of the interaction of PIM kinases and cMYC in MV4-11
cells. MV4-11 cells were lysed and the lysates treated with IP-optimized antibodies for PIM-3
(Lane 1), PIM-2 (Lane 2), PIM-1 (Lane 3), and cMYC (Lane 4) as described in materials and
methods. Protein-G-agarose beads were used for precipitation. Precipitates were washed 4 times
with cold PBS before SDS-PAGE analysis as described in materials and methods. Blots were
treated with cMYC antibody for analysis of cMYC expression and possible PIM-cMYC
interactions. Separate lysates were treated with beads alone (Lane 6) and beads+AXL (Lane 5) as
negative controls. Note that PIM-1 alone (Lane 3) interacts with cMYC as in the positive control
(Lane 4). C, KASUMI-1 cells were analyzed as in B. Lane 1-PIM-3, Lane 2-PIM-2, Lane 3PIM-1, Lane 4-cMYC, Lane 5-AXL, Lane 6-beads alone. D, ARP-1 cells were analyzed as in B.
Lane 1-PIM-3, Lane 2-PIM-2, Lane 3-PIM-1, Lane 4-cMYC, Lane 5-AXL, Lane 6-beads alone.
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Figure 2.2: PIM-1 siRNA or TP-3654 decreases the PIM-1-cMYC interaction in AML and MM
Cell Lines. A, MV4-11 cells were prepared at 1x106 cells in 6-well plates and treated with PIM-1
siRNA, using either 6 or 9µL of Lipofectamine 2000 transfection reagent as described in
materials and methods. Lysates were analyzed for PIM-1 expression to confirm knockdown. IP
reactions were carried out in the same manner as described previously, using PIM-1 IPoptimized antibody and protein-G-agarose beads as described in materials and methods. Blots
were treated with cMYC primary and mouse secondary antibodies as described in materials and
methods. B, ARP-1 cells were prepared at 2x106 cells in 6 well plates and immediately treated
with 3µM (Lane 1), 1µM (Lane 2), 300nM (Lane 3), 30nM (Lane 4), 3nM (Lane 5), or vehicle
(Lane 6) of TP-3654 for 12 hours prior to lysis, as described in materials and methods. IP
reactions were carried out with PIM-1 and cMYC as described in A. C, MV4-11 cells were
prepared and drug treated in the same manner as described in B.
Figure 2.3: TP-3654 Induces Apoptosis in AML and MM Cell Lines. MV4-11 or ARP-1 cells
were seeded at 2x106 cells per well in 6 well plates and immediately treated with the specified
concentrations of TP-3654. Cells incubated with the drug for 24 hours prior to lysis. Cells were
lysed and Western blots run as described in materials and methods. Blots were assayed for
caspase-3 expression to test for apoptotic (cleaved caspase-3) activity in drug treated cells.
Figure 3.1: TP-0903 is a potent AXL kinase inhibitor. Biochemical kinase assays were utilized to
determine IC50 values for TP-0903 against the AXL and MERTK kinases. Reactions were run
using Invitrogen’s TR-FRET LanthaScreen assay and using ATP concentrations at the apparent
Km for each kinase.
Figure 3.2: TP-0903 reduces pAKT levels upon GAS6 stimulation independent of sAXL levels.
A: Pancreatic cancer cell lines (PSN-1 and PL45) were serum starved overnight, treated for 2
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hours with TP-0903, and stimulated with Gas6 for 5 minutes. Lysates from these cells were
analyzed for total-Akt, phospho-Akt (Ser473) (A), or soluble AXL (B) using the Meso Scale
Discovery platform.
Figure 3.3: Cell migration is reduced with AXL inhibitor TP-0903. Images of fixed and crystal
violet stained cells after culturing in migration assays in control or drug-treated conditions.
Graph indicates the extent of altered migration versus controls, with P values calculated from
data generated from three independent experiments.
Figure 3.4: TP-0903 effectively induces apoptosis in both the PANC-1 and PSN-1 cell lines
within 24 hours at concentrations as low as 0.1µM. The data shown are percentages of apoptotic
cells as measured by flow cytometry gating software, used according to the protocol from
Invitrogen. 3µM cisplatin was used as a positive control in this experiment, as shown in the 3µM
group.
Figure 3.5: TP-0903 effectively suppresses expression of EMT marker genes in pancreatic
cancer cell lines. The pancreatic cancer cell lines PSN-1 (A, C) and PANC-1 (B, D) were seeded
at 1x106 cells per well in 6-well plates and allowed to grow for 6 hours before treating with the
specified concentrations of TP-0903. For real-time PCR analysis (A, B), RNA isolation was
performed 2 hours after drug treatment using the RNeasy kit (QIAGEN) including treatment
with DNase to eliminate gDNA contamination. Real-time PCR reactions were carried out using
commercially available primers optimized for SYBR-Green (QIAGEN quantitect primer assay)
for E-cadherin, snail, and twist and a One-Step SYBR-Green to Ct kit (Invitrogen). The data
shown in graphs A and B are averages with corresponding SEMs from two independent
experiments. For western blot analysis (C, D), cells were seeded and treated with 1, .3, .1, .03,
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and .01µM of TP-0903 and cells were lysed (Cell Signaling) 24 hours after drug treatment.
Western blots were carried out as described in materials and methods.
Figure 3.6: Soluble AXL is a potential marker for metastatic cancer progression. A-B: The
evaluation of Axl expression at the mRNA (by RT-PCR), protein (by western blot), and sAxl (by
ELISA) levels. These results suggest a good correlation between the three (r2 = 0.61 for mRNA
to sAxl). C: Serum samples from cancer patients were evaluated for sAxl levels. The results
indicate a statistically significant difference between the mean of the control (CTL) group and
the PDA (panc) group (p < 0.05). Furthermore, there appears to be a subgroup of colon, lung,
and PDA patients with particularly high sAxl levels.
Figure 3.7: TP-0903 reduces tumor volume in PSN-1 xenograft studies and displays favorable
oral pharmacokinetics. A-B, In vivo xenograft studies of PSN-1 pancreatic cancer cells showed a
significant reduction in tumor volume (p<0.001) but an insignificant decrease in overall body
weight (p>0.1) by Student’s t-test. C, Pharmacokinetic studies indicated favorable
bioavailability.
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TABLES
Table 1.1: Biochemical,a FLT3b, and hERGc potency comparison of TP-3654 and SGI-1776
Compound

PIM1 Ki (nM)

PIM2 Ki (nM)

PIM3 Ki (nM)

FLT3 IC50 (nM)

hERG IC50 (µM)

MW

SGI-1776

12

980

20

3

<1

405

TP-3654

5

239

42

279

>30

419

a

Ki determined by Reaction Biology, as described in the materials and methods section. bFLT3

IC50 determined by Reaction Biology, as described in the materials and methods section.
c

hERG IC50 determined by WuXi AppTec using the QPatchHTX functional hERG assay described

in the materials and methods section.
Table 1.2: PIM kinase expression in urothelial carcinoma
PIM-1

PIM-2

PIM-3

Type

Total N

# Positive

%

# Positive

%

# Positive

%

NILG

21

9

43%

7

33%

11

52%

NIHG

32

12

38%

20

63%

9

28%

IHG

84

10

12%

32

38%

11

13%

Number of cases staining positive (score 2-4) or negative (score 0-1) in non-invasive low grade
urothelial carcinoma (NILG), non-invasive high grade urothelial carcinoma (NIHG), and
invasive high grade urothelial carcinoma (IHG).
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Figure 1.1: Structure and Analysis of TP-3654
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Figure 1.2: Validation of PIM-1 in solid tumor models in vitro
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Figure 1.4: PIM-2 Kinase Expression in Urothelial Carcinoma Cases
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Figure 3.1: TP-0903 is a potent AXL kinase inhibitor
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Figure 3.2: TP-0903 reduces pAKT levels upon GAS6 stimulation
independent of sAXL levels
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Figure 3.3: Cell migration is reduced with AXL inhibitor TP-0903
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Figure 3.5: TP-0903 effectively suppresses expression of EMT marker genes in pancreatic
cancer cell lines
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